易误诊为ALCL的CD30阳性DLBCL 1例并文献复习
Diffuse Large B-Cell Lymphoma with CD30-Positive Easily Misdiagnosed as ALCL: 1 Case Report and Literature Review
DOI: 10.12677/ACM.2024.141222, PDF,    科研立项经费支持
作者: 陈 卓:延安大学医学院,陕西 延安;张 巍, 李文生*:陕西省人民医院,陕西 西安
关键词: 淋巴瘤大细胞CD30鉴别诊断Lymphoma Large Cell CD30 Differential Diagnosis
摘要: 目的:提高对CD30阳性的弥漫大B细胞淋巴瘤(DLBCL)的认识。方法:回顾性分析2022年4月陕西省人民医院收治1例免疫组织化学染色CD30弥漫表达的DLBCL患者的临床资料,并进行文献复习。结果:患者为76岁男性,于外院行超声检查提示颈部3、4区淋巴结肿大,并行颈部淋巴结穿刺活检,结合其组织形态学特点及免疫组织化学染色等诊断为CD30阳性的弥漫大B细胞淋巴瘤。予BV联合CHP方案化疗2疗程,CHOP联合来那度胺方案化疗6疗程,患者肿大淋巴结较前明显缩小,疗效评估接近完全缓解。结论:CD30弥漫阳性的DLBCL较为罕见,其免疫表型及组织学形态与经典型ALCL相似,应尽早行组织病理学检查,明确诊断,尽早治疗。
Abstract: Objective: To enhance understanding of CD30-positive Diffuse Large B-Cell Lymphoma (DLBCL). Methods: A retrospective analysis was conducted on the clinical data of a patient with immuno-histochemically stained CD30-positive DLBCL, treated in April 2022 at the Shaanxi Provincial Peo-ple’s Hospital. This included a review of relevant literature. Results: The patient, a 76-year-old male, presented with enlarged lymph nodes in regions 3 and 4 of the neck, as identified by ultrasound examination in another hospital. A neck lymph node biopsy, combined with histomorphological characteristics and immunohistochemical staining, led to the diagnosis of CD30-positive DLBCL. The patient underwent two cycles of chemotherapy with the BV + CHP regimen and six cycles with the CHOP + Lenalidomide regimen. There was a significant reduction in the size of the enlarged lymph nodes, and the therapeutic effect was assessed as nearing complete remission. Conclusion: CD30-positive DLBCL is relatively rare, with an immunophenotype and histological morphology similar to classical Anaplastic Large Cell Lymphoma (ALCL). Early histopathological examination for definitive diagnosis and prompt treatment is recommended.
文章引用:陈卓, 张巍, 李文生. 易误诊为ALCL的CD30阳性DLBCL 1例并文献复习[J]. 临床医学进展, 2024, 14(1): 1541-1546. https://doi.org/10.12677/ACM.2024.141222

参考文献

[1] 王晓卿, 徐钢, 李娟, 等. 淋巴瘤589例构成分析[J]. 临床与实验病理学杂志, 2011, 27(12): 1356-1358. [Google Scholar] [CrossRef
[2] Sabattini, E., Bacci, F., Sagramoso, C. and Pileri, S.A. (2010) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues in 2008: An Overview. Pathologica, 102, 83-87.
[3] 李小秋. CD30在淋巴瘤中的表达及检测: 现状与挑战[J]. 中国癌症杂志, 2022, 32(6): 512-518. [Google Scholar] [CrossRef
[4] Hoffbrand, A., Catovsky, D., Tuddenham, E., et al. (2010) Appendix II: World Health Organization Classification of Tumours of the Haematopoietic and Lymphoid Tissues.
https://www.who.int/publications/i?publishingoffices=c09761c0-ab8e-4cfa-9744-99509c4d306b
[5] Falini, B., Pileri, S., Pizzolo, G., et al. (1995) CD30 (Ki-1) Molecule: A New Cytokine Receptor of the Tumor Necrosis Factor Re-ceptor Superfamily as a Tool for Diagnosis and Immunotherapy. Blood, 85, 1-14. [Google Scholar] [CrossRef
[6] Slack, G.W., Steidl, C., Sehn, L.H. and Gascoyne, R.D. (2014) CD30 Expression in de novo Diffuse Large B-Cell Lymphoma: A Population-Based Study from British Columbia. British Journal of Haematology, 167, 608-617. [Google Scholar] [CrossRef] [PubMed]
[7] Hu, S., Xu-Monette, Z.Y., Balasubramanyam, A., et al. (2013) CD30 Ex-pression Defines a Novel Subgroup of Diffuse Large B-Cell Lymphoma with Favorable Prognosis and Distinct Gene Expression Signature: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 121, 2715-2724. [Google Scholar] [CrossRef] [PubMed]
[8] Muris, J.J., Meijer, C.J., Vos, W., et al. (2006) Immunohisto-chemical Profiling Based on Bcl-2, CD10 and MUM1 Expression Improves Risk Stratification in Patients with Primary Nodal Diffuse Large B Cell Lymphoma. The Journal of Pathology, 208, 714-723. [Google Scholar] [CrossRef] [PubMed]
[9] Lu, T.X., Gong, Q.X., Wang, L., et al. (2015) Immunohistochemical Algo-rithm Alone Is Not Enough for Predicting the Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Clinical and Experimental Pathology, 8, 275-286.
[10] Iqbal, J., Greiner, T.C., Patel, K., et al. (2007) Dis-tinctive Patterns of BCL6 Molecular Alterations and Their Functional Consequences in Different Subgroups of Diffuse Large B-Cell Lymphoma. Leukemia, 21, 2332-2343. [Google Scholar] [CrossRef] [PubMed]
[11] Davis, R.E., Brown, K.D., Siebenlist, U. and Staudt, L.M. (2001) Con-stitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell-Like Diffuse Large B Cell Lymphoma Cells. Journal of Experimental Medicine, 194, 1861-1874. [Google Scholar] [CrossRef] [PubMed]
[12] Hu, S., Xu-Monette, Z.Y., Tzankov, A., et al. (2013) MYC/BCL2 Protein Coexpression Contributes to the Inferior Survival of Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma and Demonstrates High-Risk Gene Expression Signatures: A Report from The International DLBCL Rituximab-CHOP Consortium Program. Blood, 121, 4021-4250. [Google Scholar] [CrossRef] [PubMed]
[13] 贡其星. CD30阳性弥漫大B细胞淋巴瘤的临床病理学研究[D]: [博士学位论文]. 南京: 南京医科大学, 2017.
[14] 陈燕坪, 倪慕兰, 柯龙凤, 等. 伴PAX5拷贝数增加的PAX5阳性间变性大细胞淋巴瘤临床病理特征[J]. 中华病理学杂志, 2022, 51(11): 1155-1157. [Google Scholar] [CrossRef] [PubMed]
[15] Aizawa, S., Nakano, H., Ishida, T., et al. (1997) Tumor Necrosis Factor Receptor-Associated Factor (TRAF) 5 and TRAF2 Are Involved in CD30-Mediated NFκB Ac-tivation. Journal of Biological Chemistry, 272, 2042-2045. [Google Scholar] [CrossRef] [PubMed]